Santhera Pharmaceuticals Reports Strong FY25 Performance and AGAMREE Expansion
Santhera Pharmaceuticals reported a significant increase in FY25 revenues, nearly doubling to CHF 77.2 million, driven by AGAMREE sales in Europe and contributions from US and Chinese partners. The company also announced plans for expansion into Spain and Italy, with improved operating expenses and a path to cash flow breakeven in Q3 2026.
Topics: AGAMREE biotech Europe markets financial performance pharmaceuticals revenue growth